Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

Levodopa

Known as: beta-(3,4-Dihydroxyphenyl)-L-alanine, 3,4-Dihydroxy-L-phenylalanine, .beta.-(3,4-Dihydroxyphenyl)-L-alanine 
An amino acid precursor of dopamine with antiparkinsonian properties. Levodopa is a prodrug that is converted to dopamine by DOPA decarboxylase and… Expand
National Institutes of Health

Related topics

Related topics

37 relations

Narrower (19)

2,4,5-trihydroxyphenylalanine quinone2,4-dihydroxyphenylalanine3,4,6-trihydroxyphenylalanine quinone3-O-methyl-6-fluoro-dopa
Expand

Broader (2)

Antiparkinson AgentsDopa
Carbidopa 10 MG / Levodopa 100 MG Disintegrating Oral TabletCarbidopa 10 MG / Levodopa 100 MG Oral TabletCarbidopa 10 MG / Levodopa 100 MG Oral Tablet [Sinemet]Carbidopa 25 MG / Levodopa 100 MG Disintegrating Oral Tablet
Expand

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2019
Review
2019
Emerging therapies in Parkinson disease — repurposed drugs and new approaches
Parkinson disease (PD) treatment options have conventionally focused on dopamine replacement and provision of symptomatic relief… Expand
  • table 1
  • table 2
  • figure 1
  • table 3
  • table 4
Is this relevant?
Highly Cited
2006
Highly Cited
2006
A randomized trial of deep-brain stimulation for Parkinson's disease.
BACKGROUND Neurostimulation of the subthalamic nucleus reduces levodopa-related motor complications in advanced Parkinson's… Expand
  • figure 1
  • table 1
  • table 2
  • figure 2
  • table 4
Is this relevant?
Review
2005
Review
2005
Diagnosis and management of dementia with Lewy bodies
The dementia with Lewy bodies (DLB) Consortium has revised criteria for the clinical and pathologic diagnosis of DLB… Expand
  • table 1
  • table 2
  • table 3
Is this relevant?
Highly Cited
2003
Highly Cited
2003
Slower progression of Parkinson's disease with ropinirole versus levodopa: The REAL-PET study.
Preclinical studies suggest ropinirole (a D2/D3 dopamine agonist) may be neuroprotective in Parkinson's disease (PD), and a pilot… Expand
Is this relevant?
Highly Cited
2003
Highly Cited
2003
Five-year follow-up of bilateral stimulation of the subthalamic nucleus in advanced Parkinson's disease.
BACKGROUND Although the short-term benefits of bilateral stimulation of the subthalamic nucleus in patients with advanced… Expand
  • table 1
  • table 2
  • figure 1
  • table 3
  • table 4
Is this relevant?
Highly Cited
2001
Highly Cited
2001
Functional Imaging of Neural Responses to Expectancy and Experience of Monetary Gains and Losses
Neural responses accompanying anticipation and experience of monetary gains and losses were monitored by functional magnetic… Expand
  • figure 1
  • table 1
  • figure 2
  • table 2
  • figure 3
Is this relevant?
Review
2001
Review
2001
Pathophysiology of levodopa-induced dyskinesia: Potential for new therapies
Involuntary movements — or dyskinesias — are a debilitating complication of levodopa therapy for Parkinson's disease that is… Expand
Is this relevant?
Highly Cited
2000
Highly Cited
2000
A five-year study of the incidence of dyskinesia in patients with early Parkinson's disease who were treated with ropinirole or levodopa.
Background There is debate about whether the initial treatment for patients with Parkinson's disease should be levodopa or a… Expand
  • figure 1
  • figure 2
  • figure 3
Is this relevant?
Highly Cited
2000
Highly Cited
2000
Pramipexole vs levodopa as initial treatment for Parkinson disease: A randomized controlled trial. Parkinson Study Group.
CONTEXT Pramipexole and levodopa both ameliorate the motor symptoms of early Parkinson disease (PD), but no controlled studies… Expand
  • table 2
  • table 3
  • figure 3
  • table 5
  • figure 5
Is this relevant?
Review
2000
Review
2000
Levodopa motor complications in Parkinson's disease
Parkinson's disease (PD) is an age-related neurodegenerative disorder with an average onset age of 60 years. In the United States… Expand
Is this relevant?
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy, Terms of Service, and Dataset License
ACCEPT & CONTINUE